S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Aratana TherapeuticsUrovant SciencesCyclerion TherapeuticsNuCanaForty Seven
SymbolN/ANASDAQ:UROVNASDAQ:CYCNNASDAQ:NCNANASDAQ:FTSV
Price Information
Current PriceN/A$9.53$10.87$6.88$6.26
52 Week RangeHoldBuyHoldBuyBuy
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$4.73$24.00N/A$23.33$25.50
% Upside from Price Target∞ upside151.84% upsideN/A239.15% upside307.35% upside
Trade Information
Market Cap$241.08 million$291.87 million$282.43 million$214.53 million$259.65 million
Beta1.4N/AN/A3.131.87
Average Volume1,030,94652,314161,01366,870210,780
Sales & Book Value
Annual Revenue$35.41 millionN/AN/AN/AN/A
Price / Sales0.00N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.07 per share$2.47 per shareN/A$3.42 per share$4.29 per share
Price / Book0.00N/AN/AN/AN/A
Profitability
Net Income$-14,720,000.00$-111,350,000.00$-115,250,000.00$-18,470,000.00$-70,370,000.00
EPS($0.32)($4.43)N/A($0.57)($3.75)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-33.47%N/AN/AN/AN/A
Return on Equity (ROE)-12.99%-199.22%N/A-19.99%-70.48%
Return on Assets (ROA)-10.82%-142.39%N/A-18.62%-61.40%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.29%0.51%N/AN/A
Current Ratio6.66%6.20%6.60%11.34%4.96%
Quick Ratio5.32%6.20%6.60%11.34%4.96%
Ownership Information
Institutional Ownership Percentage65.00%24.10%70.94%36.06%36.17%
Insider Ownership Percentage5.30%2.40%N/AN/A37.40%
Miscellaneous
Employees8317N/A2157
Shares Outstanding49.00 million30.34 million27.42 million32.26 million42.22 million
Next Earnings Date10/30/2019 (Estimated)11/11/2019 (Estimated)11/11/2019 (Estimated)11/26/2019 (Estimated)11/12/2019 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
 Aratana TherapeuticsUrovant SciencesCyclerion TherapeuticsNuCanaForty Seven

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel